Physiomics plc announced that Dr. Christophe Chassagnole's job title has changed from Chief Operating Officer to Chief Scientific Officer. This title aligns more closely with Dr. Chassagnole's current role and responsibilities and the expectation that, going forward, he will spend more time focused on the Company's personalised medicines initiatives. The change builds on the ongoing restructuring of the board which commenced last year with the hiring of two highly experienced Non-Executive Directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 GBX | +7.69% | +7.69% | -12.50% |
07/06 | Physiomics wins "significant" GBP160,000 contract | AN |
07/06 | Physiomics Secures Virtual Tumor Technology Deal With UK Biotech Company | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.50% | 2.25M | |
-2.67% | 136B | |
+21.33% | 77.51B | |
-13.08% | 39.06B | |
+16.20% | 38.98B | |
-5.67% | 29.55B | |
-14.07% | 15.63B | |
+3.78% | 14.23B | |
+11.32% | 10.62B | |
-18.80% | 4.22B |
- Stock Market
- Equities
- PYC Stock
- News Physiomics Plc
- Physiomics plc Announces Change of Job Title of Dr. Christophe Chassagnole from Chief Operating Officer to Chief Scientific Officer